Meisner Lara's Form 4 filing
Viridian Therapeutics, Inc.DEVRDN · filed Jan 25, 2023
- Accession no.
- 0000899243-23-002674
- Filed
- Jan 25, 2023
- Trade date
- Jan 23, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $244.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meisner LaraCIK 0001883986 | Officer (General Counsel and Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2023 | Common Stock | MOption exerciseAcquired | +4,971 | $23.03 | +$114,482.13 | 4,971 | Direct | |
| Jan 23, 2023 | Common Stock | MOption exerciseAcquired | +1,872 | $14.00 | +$26,208 | 6,843 | Direct | |
| Jan 23, 2023 | Common Stock | SSaleDisposed | −6,843 | $35.66F1 | −$244,021.38 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2023 | Common Stock | MOption exerciseDisposed | −4,971 | $0.00 | $0 | 39,750 | Direct | |
| Jan 23, 2023 | Common Stock | MOption exerciseDisposed | −1,872 | $0.00 | $0 | 20,003 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.